Loading patent…
AssigneeSingapore Health Services Pte Ltd
InventorsSuk Peng CHEW, Salvatore ALBANI, Kah-Hoe Pierce CHOW, Lu PAN
Estimating the term…
A method for the prognosis of response to treatment for a patient suffering from cancer, the method comprising: measuring the expression of at least one immune marker in a leukocyte sample taken from the patient with cancer; classifying the patient sample into (i) sustainable responders (SR) to selective internal radiation therapy (SIRT) or (ii) transient/non-responders (TR/NR) to (SIRT) based on expression of the at least one immune marker in relation to a predetermined value and treating sustainable responders (SR) to SIRT or SIRT or a composition comprising SIRT and an immunotherapy. In a preferred embodiment, the method is for the prognosis of response to treatment of a Hepatocellular carcinoma (HCC) patient comprising detecting the co-expression of PD-1 or Tim-3 with CCR5; or expression of PD-1, Tim-3, CXCR6, or combinations thereof in a leukocyte sample taken from the patient.
-24. (canceled)
An in vitro method for the prognosis of response to treatment for a patient suffering from cancer, the method comprising:
A system for prognosing a response to treatment for a patient suffering from cancer, the system comprising:
A method of treating a patient with cancer that is prognosed as a sustained responders (SR) to radioembolization (RE) comprising administering a therapeutically effective dose of a composition comprising a RE and an immunotherapy to the patient.
Dependencies are inferred from the claim text.